article Open AccessTop 1% cited

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

JNCI Journal of the National Cancer Institute · 2012 · Vol. 104(2) · pp. 125–132

G. L. Andriole✉(Washington University in St. Louis)E. David Crawford(University of Colorado Denver)Robert L. Grubb(Georgetown University)Saundra S. Buys(University of Alabama at Birmingham)David Chia(Georgetown University)Timothy R. Church(University of Alabama at Birmingham)Mona N. Fouad(Georgetown University)Claudine Isaacs(Georgetown University)Paul A. Kvale(University of Alabama at Birmingham)Douglas J. Reding(Georgetown University)Joel L. Weissfeld(University of Pittsburgh)Lance Yokochi(University of Alabama at Birmingham)Barbara O’Brien(Westat (United States))Lawrence R. Ragard(Georgetown University)Jonathan D. Clapp(Information Management Services)Joshua Rathmell(Georgetown University)T. Riley(Information Management Services)Ann W. Hsing(Georgetown University)Grant Izmirlian(Georgetown University)Paul F. Pinsky(University of Alabama at Birmingham)B S Kramer(National Institutes of Health)Andrea Miller(Georgetown University)John K. Gohagan(Georgetown University)Philip C. Prorok(National Institutes of Health)for the PLCO Project Team

View via DOI Full-text PDF

Abstract

After 13 years of follow-up, there was no evidence of a mortality benefit for organized annual screening in the PLCO trial compared with opportunistic screening, which forms part of usual care, and there was no apparent interaction with age, baseline comorbidity, or pretrial PSA testing.

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Colorectal Cancer Screening and DetectionMedicineRandomized controlled trialOncologyColorectal cancerProstateProstate cancerInternal medicineLung cancerCancerGynecology

MeSH terms

Age FactorsAgedFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMass ScreeningMiddle AgedOvarian NeoplasmsProstatic NeoplasmsRiskBiomarkers, TumorColorectal NeoplasmsComorbidity